VAXNEUVANCE® is a pioneering pneumococcal conjugate vaccine developed by Merck & Co. It is designed to provide immunization against infections caused by Streptococcus pneumoniae, particularly those caused by 15 different serotypes. This vaccine is a significant advancement in the prevention of pneumococcal diseases, especially in vulnerable population. Here we will explore the formulation, uses, advantages, side effects, dosage, precautionary measures, and pricing of VAXNEUVANCE® in the UK and US in detail.
Formulation of VAXNEUVANCE®
VAXNEUVANCE® is formulated as a suspension for intramuscular injection. Each dose contains:
Pneumococcal polysaccharides from 15 different serotypes conjugated to a carrier protein, enhancing the immune response in the body.
Key Ingredients:
- Pneumococcal Polysaccharides: The specific serotypes included in the formulation are designed to protect against the most common strains causing serious infections.
- Carrier Protein: Conjugation to a protein enhances immunogenicity, especially in infants and young children.
Uses of VAXNEUVANCE®
- VAXNEUVANCE® is primarily indicated for the prevention of pneumococcal diseases caused by the 15 included serotypes, which may lead to:
- Pneumonia
- Meningitis
- Bloodstream infections (bacteremia)
- Acute otitis media (middle ear infections)
Advantages of VAXNEUVANCE®
- Broad Coverage: Protects against 15 serotypes, offering a wider range of immunity compared to earlier vaccines.
- Effective in Vulnerable Populations: Provides critical protection for infants, elderly individuals, and those with weakened immune systems.
- Conjugate Vaccine Technology: Enhances the immune response, leading to long-lasting immunity.
Side Effects of VAXNEUVANCE®
Most individuals tolerate VAXNEUVANCE® well, but some may experience mild side effects, including:
- Pain or swelling at the injection site
- Fever
- Fatigue
- Headache
Dosage of VAXNEUVANCE®
The recommended dosage schedule for VAXNEUVANCE® varies based on age and health status:
- For Infants and Young Children: A series of doses starting at 2 months of age, typically administered at 2, 4, and 12-15 months.
- For Adults: A single dose may be recommended, especially for those with underlying health conditions.
Precautionary Measures of VAXNEUVANCE®
Before vaccination, healthcare providers should consider:
- Allergy History: Assess for any previous allergic reactions to vaccines.
- Current Illnesses: Individuals with moderate to severe illnesses may need to postpone vaccination.
- Immunocompromised Status: Patients with weakened immune systems should discuss their vaccination plan with a healthcare professional.
Year of invention of VAXNEUVANCE®
VAXNEUVANCE® was approved by the U.S. Food and Drug Administration (FDA) in 2021, representing a significant milestone in pneumococcal vaccination. VAXNEUVANCE® was approved by the FDA in June 2021. It was developed to provide protection against pneumococcal disease caused by 15 different serotypes of Streptococcus pneumoniae
Company Information of VAXNEUVANCE®
VAXNEUVANCE® is manufactured by Merck & Co., a global leader in healthcare innovation with over a century of experience. The company is dedicated to developing vaccines and therapies that improve health outcomes worldwide.
Price in USA and UK of VAXNEUVANCE®
As of 2024, the price of VAXNEUVANCE® can vary based on factors such as location and healthcare provider:
- USA: The cost typically ranges from $200 to $300 per dose, depending on the provider and insurance coverage.
- UK: In the NHS, the vaccine is often provided free of charge as part of the routine immunization schedule. Private treatment may cost around £150 per dose.
Conclusion
VAXNEUVANCE® is a crucial addition to the arsenal against pneumococcal diseases, offering broad protection and helping to reduce the burden of serious infections. As always, individuals should consult healthcare professionals for personalized vaccination advice and to discuss any concerns related to immunization.
